ReviewDrugs in context2022
Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.
Eleanor Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
27 papers cite it
this paperpooled ittrialcites it